Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 46489 

Development Status: Preclinical data 

is available at this time. 

Inventors: Yasutaka Hoshino and 

Albert Z. Kapikian (NIAID). 

Related Publications: 

1. Y Hoshino, RW Jones, J Ross, AZ 

Kapikian. Porcine rotavirus strain 

Gottfried-based human rotavirus 

candidate vaccines: construction and 

characterization. Vaccine 2005 May 

31;23(29):3791–3799. 

2. M Gorziglia, K Nishikawa, Y 

Hoshino, K Taniguchi. Similarity of the 

outer capsid protein VP4 of the 

Gottfried strain of porcine rotavirus to 

that asymptomatic human rotavirus 

strains. J Virology, 1990 Jan;64(1):414–

418. 

Patent Status: U.S. Provisional 

Application No. 60/698,572 filed 11 Jul 

2005 (HHS Reference No. E–056–2005/ 

0–US–01) 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Chekesha 

Clingman, Ph.D.; 301/435–5018; 

clingmac@mail.nih.gov. 

Adoptive T-Cell Transfer After 

Lymphodepletion Promotes Tumor 

Regression 

Description of Technology: Available 

for licensing is a method of adoptive 

cell transfer (ACT) immunotherapy. 

Since its first description, ACT is now 

being developed for the supportive 

treatment of a variety of infectious 

diseases and cancer. 

Current ACT methods to treat cancer 

are based on the ex vivo selection of 

lymphocytes with high avidity for 

recognition of tumor antigens, and their 

activation and numerical expansion 

before re-infusion to the autologous 

tumor-bearing host. The current 

invention improves ACT by including a 

pre-treatment regimen to ensure 

permissive conditions in the host for in 

vivo proliferation of the transferred 

cells. Specifically, the immune system 

is suppressed by pre-treatment with 

lymphodepleting chemotherapy. Two 

separate clinical trials have 

demonstrated that using this approach, 

ACT can induce lasting tumor 

shrinkage. 

Lymphodepleting chemotherapy 

followed by ACT resulted in tumor 

shrinkage of at least 50 percent in 6 out 

of 13 treated patients suffering from 

refractory melanoma. Several patients 

remained cancer free for more than a 

year after treatment. The usefulness of 

combined ACT and lymphodepleting 

therapy for cancer treatment was 

confirmed when this study was 

extended to include 35 melanoma 

patients. Eighteen of the 35 patients 

(51%) responded to the treatment, 

including 3 patients who experienced 

ongoing complete disappearance of 

cancer and 15 patients had tumor 

shrinkage of at least 50 percent with a 

mean duration of almost a year after 

treatment. In a recent clinical trial that 

is not yet published, using a modified 

protocol to treat 23 patients, a similar 

response rate (56%) was seen. 

This approach to ACT offers a 

potentially significant improvement in 

the treatment of many types of cancer. 

In addition, this method might be 

applicable in treating other diseases 

such as AIDS, immunodeficiency, or 

other autoimmunity for which immune 

effector cells can impact the clinical 

outcome. 

Inventors: Mark E. Dudley, Steven A. 

Rosenberg, John R. Wunderlich (NC). 

Publications: 

1. Dudley ME, et al. ‘‘Adoptive cell 

transfer therapy following nonmyeloablative but lymphodepleting 

chemotherapy for the treatment of 

patients with refractory metastatic 

melanoma.’’ J Clin Oncol. 2005 Apr 

1;23(10):2346–2357. 

2. Dudley ME, et al. ‘‘Cancer 

regression and autoimmunity in patients 

after clonal repopulation with antitumor 

lymphocytes.’’ Science. 2002 Oct 

25;298(5594):850–854. 

Patent Status: U.S. Provisional 

Application No. 60/408,681 filed 06 Sep 

2002 (HHS Reference No. E–275–2002/ 

0–US–01); PCT Application No. PC/ 

US03/27873 filed 05 Sep 2003, which 

published as WO 2004/021995 on 18 

Mar 2004 (HHS Reference No. E–275–

2002/1–PCT–01); U.S. Patent 

Application No. 10/526,697 filed 05 

May 2005 (HHS Reference No. E–275–

2002/1–US–02). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Michelle A. 

Booden, Ph.D.; 301/451–7337; 

boodenm@mail.nih.gov. 

Collaborative Research Opportunity: 

The NCI Surgery Branch is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize ACT therapy. Please 

contact Steven A. Rosenberg, M.D., 

Ph.D. at 301/496–4164 for more 

information. 

Dated: July 28, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–6872 Filed 8–11–06 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Hollow Waveguide Laser Delivery 

System for Digital Particle Image 

Velocity 

Description of Technology 

Available for licensing and 

commercial development is an allhollow-waveguide laser delivery system 

used for effective digital particle image 

velocimetry (DPIV) illumination. The 

System incorporates two key optical 

hollow waveguide components: An 

uncoated funnel-shaped hollow glass 

taper for a direct laser-to-taper coupling 

and a flexible hollow core waveguide 

for precise high-peak-power laser 

delivery. The principle of operation of 

the uncoated hollow taper is based on 

grazing-incidence effect. The optical 

taper is used for direct lens-free 

launching of laser radiation including 

from powerful lasers into fibers and 

waveguides. Because of the mutual 

action of the direct parallel laser 

excitation, the mode coupling process 

and mode filtering effect, the hollow 

taper serves as a mode converter that 

transforms the highly multimode profile 

of the input laser emission into a highquality Gaussian-shaped profile at the 

taper output. Moreover, because of the 

lower power density of the output laser 

beam and its high causality profile, the 


jlentini on PROD1PC65 with NOTICES
46490 Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 

taper ensures higher damage threshold 

for the delivery waveguide in 

comparison to the conventional lens 

laser-to-fiber coupling. To improve the 

high-peak-power delivery capability of 

the proposed allow-hollow-waveguide 

DPIV illumination system, instead of a 

conventional solid-core fiber link, we 

have used a cyclic olefin polymer 

(COP)-coated hollow glass waveguide 

which is designed to minimize the 

waveguide attenuation losses at a 

typical DPIV laser wavelength of 532- 

nm. This waveguide provides a 

significantly higher laser power delivery 

capability and higher damage threshold. 

The all-hollow-waveguide DPIV laser 

delivery system offers essential 

advanced features over conventional 

bulk-optics-based delivery techniques in 

terms of formatting thin (0.5–1.0 mm), 

wide (10 mm or wider) and uniform 

laser illumination sheet; high-peakpower laser delivery without damaging 

effects (> 1 GW/cm2), flexibility, 

miniaturization, simplified alignment, 

immunity to external influence 

(including vibrations and angular laser 

beam drift), and safe and confined laser 

delivery. 

Applications 

2. Optics; Particle imaging: 

Velocimetry. 

Market 

4. Illumination, high peak laser 

powered delivery. 

Inventors 

6. Ilko K. Ilev, Ronald A. Robinson, 

Ronald W. Waynant (FDA). 

Publications 

1. IK Ilev et al., ‘‘Grazing-IncidenceBased Hollow Taper for Infrared Laserto-Fiber Coupling,’’ Applied Physics 

Letters, Vol. 74, 1999, pp. 2921–2923. 

2. IK Ilev et al., ‘‘Uncoated Hollow 

Taper as a Single Optical Funnel for 

Laser Delivery,’’ Review of Scientific 

Instruments, Vol. 70, 1999, pp. 3840–

3843. 

3. IK Ilev et al., ‘‘Ultraviolet Laser 

Delivery Using an Uncoated Hollow 

Taper,’’ IEEE Journal of Quantum 

Electronics, Vol. 36, 2000, pp. 944–948. 

4. IK Ilev et al., ‘‘Attenuation 

Measurement of Infrared Optical Fibers 

Using a Hollow-Taper-Based Coupling 

Method,’’ Applied Optics, Vol. 39, 2000, 

pp. 3192–3196. 

5. RA Robinson et al., ‘‘Design and 

Optimization of a Flexible High-Peak 

Power Laser-to-Fiber Coupled 

Illumination System Used in Digital 

Particle Image Velocimetry’’, Review of 

Scientific Instruments, Vol. 75, 2004, 

pp. 4856–4862. 

Patent Status 

8. U.S. Provisional Application No. 

60/730,866 filed 28 Oct 2005 (HHS 

Reference No. AE–015–2006/0–US–01). 

Licensing Status 

10. Available for non-exclusive or 

exclusive licensing. 

Licensing Contact 

Michael A. Shmilovich, Esq.; 301/ 

435–5019. shmilovm.@mail.nih.gov. 

<mailto:shmilovm@mail.nih.gov.> 

Collaborative Research Opportunity 

The Food and Drug Administration’s 

Center for Devices and Radiological 

Health is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Please 

contact the inventors at 301/827–4685 

for more information. 

Dated: July 28, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer; Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–6873 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Model Th1 Clone Producing IFNgamma and IL–2 

Description of Technology 

Available for licensing is the A.E7 T 

cell clone, a model Th1 clone described 

in Matis et al., J Immunol. 1983 Apr 

130(4):1527–1535 [PubMed abs] and J 

Immunol. 1983 Sept 131(3):1049–1055 

[PubMed abs]. This clone has been 

further utilized as a model for studying 

T cell clonal anergy. 

Potential Applications of Technology 

2. Model Th1 clone capable of making 

IFN-gamma and IL–2 

4. Model T cell clone for studying T 

cell clonal anergy 

Inventors 

Ronald H. Schwartz et al. (NIAID). 

Louis A. Matis (NIAID). 

Dan L. Longo (NCI). 

Toby T. Hecht (NCI). 

Patent Status 

HHS Reference No. E–214–2006/0—

Research Tool. 

Licensing Status 

Available for non-exclusive licensing. 

Licensing Contact 

Susan Ano, Ph.D.; Phone: (301) 435–

5515; Email: anos@mail.nih.gov. 

Dated: July 31, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–6874 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditions 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 


jlentini on PROD1PC65 with NOTICES